Pfizer has reduced its production targets for the COVID-19 vaccine as it was supposed to deliver the first doses before, because it had difficulty providing all the materials it needed to produce the vaccine on large scale. Bloomberg.
Pfizer, which developed the vaccine with the German company BioNTech, announced in September that it plans to produce up to 100 million doses of the vaccine this year. But in announcements in November, the company dropped estimates to 50 million doses.
A spokesman for Pfizer explained that several factors slow down production, including the time required to obtain the large quantities of raw materials needed. However, the company said it had solved production problems at scale and is now producing vaccines at a rapid pace.
“Expanding vaccine production at this rate is unprecedented and we have made significant progress as we move into the unknown. Expanding the raw material supply chain took longer than expected,” said spokeswoman Amy Rose.
“Doses are made at a rapid pace. We are confident in our ability to deliver 1.3 billion doses by the end of 2021,” Rose added.
The two-dose vaccine, based on a technology called messenger RNA, was released in the UK this week and is licensed in the US and European Union. A clinical study of 44,000 participants showed that the vaccine was 95% effective in preventing COVID-19.
Editor: Monica Bonea